Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Eugonia.
Recruitment status was  Recruiting
Information provided by:
Eugonia Identifier:
First received: December 22, 2006
Last updated: December 28, 2006
Last verified: December 2006
The purpose of this study is to compare pregnancy rates and the occurrence of OHSS in PCOS patients who were treated with GnRH agonist and GnRH antagonist protocols ovarian stimulation during an IVF cycle. Our hypothesis is that the GnRH antagonist protocol reduces the occurrence and severity of OHSS compared to the GnRH agonist protocol.

Condition Intervention Phase
Polycystic Ovary Syndrome
Ovarian Hyperstimulation Syndrome
Drug: Arvekap 0.1mg (Triptorelin, Ipsen, France)
Drug: Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients

Resource links provided by NLM:

Further study details as provided by Eugonia:

Primary Outcome Measures:
  • Development of OHSS
  • Ongoing pregnancy rate per embryo transfer

Secondary Outcome Measures:
  • Biochemical pregnancy
  • Clinical pregnancy
  • Embryological data

Estimated Enrollment: 200
Study Start Date: November 2003
Estimated Study Completion Date: May 2007
Detailed Description:

Women with polycystic ovarian syndrome (PCOS) represent a group of patients at high risk of developing ovarian hyperstimulation syndrome (OHSS), an iatrogenic complication of ovarian stimulation during IVF treatment. In contrast to mild OHSS, severe OHSS is a life-threatening complication, characterized by massive ovarian enlargement, ascites, pleural effusion, oliguria, haemoconcentration and thromboembolic phenomena. Currently, no curative therapy for OHSS is available and thus prevention is considered the most effective “treatment”. Several measures have been adopted to reduce the occurrence of the syndrome, the most effective being cycle cancellation and withholding of human chorionic gonadotropin (hCG), which seems to be the most critical factor for the development of OHSS.

COMPARISON: This study aims to compare the development and severity of OHSS, as well as ongoing pregnancy rates in PCOS patients who received a flexible GnRH antagonist (Ganirelix) protocol vs a long GnRH agonist (Arvekap) protocol of ovarian stimulation.


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinical diagnosis of PCOS (presence of oligo-ovulation/anovulation and polycystic ovaries)

Exclusion Criteria:

  • Normal responders
  • Poor responders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00417144

Contact: Tryfon Lainas, PhD 00302107236333

Eugonia Recruiting
Athens, Greece, 11528
Contact: Tryfon Lainas, PhD    00302107236333   
Sponsors and Collaborators
Principal Investigator: Tryfon Lainas, PhD Eugonia
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00417144     History of Changes
Other Study ID Numbers: ag vs antag PCOS
Study First Received: December 22, 2006
Last Updated: December 28, 2006
Health Authority: Greece: National Organization of Medicines

Keywords provided by Eugonia:
GnRH antagonist
GnRH agonist

Additional relevant MeSH terms:
Ovarian Hyperstimulation Syndrome
Polycystic Ovary Syndrome
Adnexal Diseases
Endocrine System Diseases
Genital Diseases, Female
Gonadal Disorders
Ovarian Cysts
Ovarian Diseases
Pathologic Processes
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on November 30, 2015